Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03983057 | Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer | completed | Phase 2 | 392 | Zhejiang UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03727880 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 28 | Lei ZhengOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT03264404 |
| Azacitidine and Pembrolizumab in Pancreatic Cancer |
| completed |
| Phase 2 |
| 36 |
| Susan E. BatesOTHER |
| 1 |
| Jan 27, 2026 |
| clinicaltrials |
| NCT04524702 | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | completed | Phase 2 | 10 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05641896 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers(18F-FAPI-74 GI) | completed | Phase 2 | 109 | SOFIEINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03443492 | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer(Pancreas) | completed | Phase 2 | 130 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | completed | Phase 2 | 136 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | completed | Phase 2 | 23 | Emory UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | completed | Phase 1 / Phase 2 | 341 | Hoffmann-La RocheINDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT04054362 | Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma(PINBALL) | completed | Phase 2 | 27 | Barts & The London NHS TrustOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05052723 | Cabozantinib and Pembrolizumab in Metastatic Pancreas | completed | Phase 2 | 21 | Joseph KimOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT01489865 | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 64 | Georgetown UniversityOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03192462 | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer(TACTOPS) | completed | Phase 1 / Phase 2 | 37 | Baylor College of MedicineOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03404960 | Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy(Parpvax) | completed | Phase 1 / Phase 2 | 104 | University of PennsylvaniaOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 332 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 9, 2025 | clinicaltrials |
| NCT04257448 | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer(SEPION) | completed | Phase 1 / Phase 2 | 75 | GWT-TUD GmbHOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT00964171 | Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer(PANTER) | completed | Phase 2 | 19 | Institut BergoniéOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04191421 | Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Emory UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04409002 | Niraparib + Dostarlimab + RT in Pancreatic Cancer | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03697564 | Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 2 | Hitendra PatelOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03033225 | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT01781728 | Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT01342354 | Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04923529 | TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | completed | Phase 2 | 28 | The University of Hong KongOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02723331 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | completed | Phase 2 | 48 | Academic Thoracic Oncology Medical Investigators ConsortiumINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03693677 | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI(FUNGEMAX) | completed | Phase 2 | 288 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Jul 1, 2025 | clinicaltrials |
| NCT02078700 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | completed | Phase 2 | 40 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT03250273 | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | completed | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05481463 | Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT05222204 | DDP ip Combined With AG in PDAC With Peritoneal Metastasis | completed | Phase 2 | 91 | Fudan UniversityOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06241352 | Statin Addition to Chemotherapy for Advanced Pancreatic Cancer | completed | Phase 2 | 42 | Changhai HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03861702 | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: | completed | Phase 2 | 28 | Nelson YeeOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer(VIRAGE) | completed | Phase 2 | 112 | Theriva Biologics SLINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT02650804 | BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | completed | Phase 2 | 45 | BPGbioINDUSTRY | 2 | Mar 26, 2025 | clinicaltrials |
| NCT06111872 | Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. | completed | Phase 2 | 90 | National University of MalaysiaOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT01601808 | Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma(ViP) | completed | Phase 2 | 142 | University of LiverpoolOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04247165 | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.(LAPTOP) | completed | Phase 1 / Phase 2 | 55 | Herlev HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT02907099 | Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04386057 | LY3214996 +/- HCQ in Pancreatic Cancer | completed | Phase 2 | 52 | Kimberly Perez, MDOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03161379 | GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials